Core Insights - The 9th Idiopathic Pulmonary Fibrosis (IPF) Summit will be held in Boston from August 19 to 21, 2025, where Dongyangguang Pharmaceutical will present key data from the Phase II clinical trial of its innovative anti-fibrotic drug, HEC585 [1][2] - HEC585 is the first domestically developed IPF drug to enter Phase III clinical trials and has potential applications in various fibrotic diseases [1][5] - The drug's mechanism involves multi-target inhibition and network regulation, showing promise as a "Best in Class" treatment [2] Clinical Trial Details - The Phase II trial was a multi-center, randomized, double-blind, placebo-controlled study involving 270 participants, assessing the efficacy and safety of HEC585 in IPF patients [2] - Results indicated that the 200mg dose of HEC585 significantly delayed the decline in Forced Vital Capacity (FVC) compared to the placebo group, with a statistically significant improvement of over 80mL [2][3] - The overall safety profile of HEC585 was favorable, with adverse reactions similar to those in the placebo group, and lower incidence of skin-related side effects compared to the comparator drug [3] Market Context - IPF is a chronic, progressive disease with a median survival of only 2-3 years post-diagnosis, and the number of patients in China is projected to reach 283,600 by 2025 [4] - Currently, only two drugs are approved for IPF treatment, with limited efficacy, highlighting the need for new therapies [4] - HEC585 is the only innovative drug in China that has completed head-to-head clinical trials against pirfenidone, demonstrating superior efficacy [6]